# XCOPRI's US Sales Rise 45.6% While SK's Next Epilepsy Candidate Faces an Enrolment Hold

A profitable American franchise led Donghoon Lee to Biohaven's opakalim. The proposed worldwide licence now sits between antitrust progress and an unresolved partial clinical hold.

Canonical: https://kgcf.dsmlholdings.com/insights/sk-biopharmaceuticals-2026-q2-xcopri-commercial-scale/
Published: 2026-10-15
Modified: 2026-10-31
Author: [DSML Holdings LLC](https://www.dsmlholdings.com/)

Company: SK Biopharmaceuticals
Event: 2026-08-05
SK reported its second-quarter results on 5 August 2026. It signed the Biohaven licence on 26 August; Biohaven's 29 October update reported antitrust progress and a continuing partial clinical hold.

## Reported Metrics

- US XCOPRI quarterly sales: KRW 224.4bn. April-June 2026; up 45.6% year over year and 13.5% sequentially; 5 August 2026 company earnings release. [Source 1](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=792&currentPage=1)

- Consolidated quarterly operating profit: KRW 97.1bn. April-June 2026 on KRW 247.4bn group revenue, reported on 5 August.. [Source 1](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=792&currentPage=1)

- Q2 US total prescriptions: ~143,000. Company-reported prescription events for April-June 2026, published on 5 August.. [Source 1](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=792&currentPage=1)

- Contracted opakalim upfront schedule: USD 400m. 26 August 2026 agreement: USD 350m at closing and USD 50m one year later. Remaining closing conditions were outstanding in Biohaven's 29 October update.. [Source 5](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=794&currentPage=1)

SK Biopharmaceuticals reported Q2 2026 revenue of KRW 247.4 billion, operating profit of KRW 97.1 billion and US XCOPRI sales of KRW 224.4 billion on 5 August. Three weeks later it signed a worldwide Kv7 platform licence with Biohaven, led by opakalim. Biohaven's 29 October update said the antitrust waiting period had expired, with remaining closing conditions outstanding and a partial enrolment hold continuing.

Donghoon Lee's second-product ambition had an unusually tangible foundation: an American epilepsy organisation already selling a medicine at scale. XCOPRI's growth gave SK more than a promising clinical platform. It supplied earnings and a commercial team that could potentially serve another drug. The opakalim agreement then exposed the other side of that ambition: a successful seller still has to pay for development risk when it buys its next candidate.

Lee wanted to put another medicine through the American organisation built for XCOPRI. Coric chose that partner instead of creating Biohaven's own commercial operation. Their agreement committed SK to future development costs and staged payments, while leaving Biohaven's researchers involved in the programme. XCOPRI's earnings gave Lee the means to pursue this second-product strategy; the candidate's scientific and regulatory progress would determine what the investment could deliver.

## US XCOPRI Share of Quarterly Group Revenue

224.4 / 247.4 = 90.7%, using KRW billions reported on 5 August 2026.

US XCOPRI supplied approximately nine-tenths of SK's consolidated revenue in April-June 2026.

## A Growing Medicine Carried the Second Quarter

SK's August results showed a business becoming less dependent on an occasional licence milestone to produce a profitable quarter. US XCOPRI sales rose 45.6% from a year earlier and 13.5% from the preceding quarter. Group operating profit increased even though the one-off milestone contribution in Q1 had fallen away and selling and administrative costs had risen. The reported figures put consolidated operating margin at 39.2%, with US XCOPRI supplying 90.7% of group revenue.

The prescription figures gave that sales line an operating counterpart. Q2 total prescriptions were approximately 143,000, and June alone recorded 49,155. These are prescription events, not unique patients. They nevertheless describe a medicine being used repeatedly within an established treatment market, not initial shipments following a regulatory announcement.

The May results had already shown stronger new-patient activity, with March new-to-brand prescriptions exceeding 2,000. SK then resumed direct-to-consumer advertising in April and introduced a new advertisement in June. Management continued its awareness campaign as the established US medicine reached more patients through its commercial organisation.

1. [SK Biopharmaceuticals / Q2 2026 revenue, profit, product sales and prescription update](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=792&currentPage=1)
2. [SK Biopharmaceuticals / Q1 2026 earnings and US commercialization update](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=786&currentPage=1)

## The American Team Became an Asset Lee Wanted to Reuse

On 26 August, Lee announced the Biohaven agreement at the Westin Josun in Seoul. SK described it as the long-awaited second-product step in its marketing-infrastructure strategy. Its US subsidiary, SK Life Science, had a dedicated epilepsy field organisation of more than 150 professionals and relationships with epilepsy centres and neurologists.

That was the specific asset behind the proposed combination. Biohaven chief executive Vlad Coric did not want to build another capital-intensive commercial organisation for opakalim. Lee wanted a second differentiated treatment that could use one already built. Both companies were making a choice about where to place their resources: Biohaven would contribute its programme, while SK would bring development experience and the intended route to market.

5. [SK Biopharmaceuticals / opakalim agreement, payment schedule and US sales infrastructure](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=794&currentPage=1)
9. [Biohaven and SK / joint release, commercial organisation and financial obligations](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/exhibit991-biohavenandskbi.htm)

## The Licence Buys a Platform and Imports Its Obligations

The agreement is wider than US opakalim rights. On closing, SK would receive an exclusive, royalty-bearing worldwide licence to Biohaven's Kv7 platform, including other covered compounds and products. Opakalim activates potassium channels involved in controlling nerve-cell excitability. It remained an investigational Phase II/III epilepsy candidate, not an approved counterpart to XCOPRI.

The USD 400 million upfront schedule calls for USD 350 million at closing and USD 50 million a year later. Biohaven is also eligible for up to USD 150 million of development and regulatory milestones. SK would assume specified Knopp Biosciences and future Kv7 milestone obligations of up to USD 245 million. Together, those upfront and contingent commitments make up the USD 795 million platform headline.

Royalties remain additional: Biohaven's US rate ranges from the mid-teens to low twenties, with mid-single-digit participation outside the United States for opakalim and specified other products. The inherited Knopp royalties are separate. Biohaven's researchers would continue specified trials and regulatory work after closing. SK would reimburse specified pre-closing costs and fund agreed development activities, carrying the programme towards the intended commercial use of its American team.

7. [Biohaven / Form 8-K, payment, development and termination terms](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/bhvn-20260826.htm)
9. [Biohaven and SK / joint release, commercial organisation and financial obligations](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/exhibit991-biohavenandskbi.htm)
10. [Biohaven and SK / partial assignment, obligations effective upon closing](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/exhibit102-partialmipaassi.htm)

## September Interrupted the Second-Product Story

On 4 September, FDA issued a partial clinical hold concerning a metabolite observed in rodent testing, according to Biohaven's report signed on 9 September and filed with the SEC on 10 September. The agency wanted additional nonclinical information to assess its significance for human subjects. New enrolment paused, while already randomised patients could continue dosing. Biohaven also applied that approach voluntarily at its sites outside the United States.

The two pivotal trials were in different positions. RISE3 was already fully enrolled and randomised, so Biohaven maintained its expected second-half 2026 topline timetable. RISE2 could continue dosing enrolled patients but could not add new participants pending the additional data. The researchers could keep treating people already in their studies while the company assembled the nonclinical work needed to resume recruitment.

SK's 10 September response said the finding had been examined during diligence before signing. Management and outside experts considered it potentially specific to rodents, but additional studies and regulatory assessment were still needed. The company also said the transaction had not closed. Lee's commercial team could offer a route to patients if opakalim succeeded; it could not answer the metabolite question through sales expertise.

6. [SK Biopharmaceuticals / opakalim partial clinical hold and pre-closing status notice](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=800&currentPage=1)
8. [Biohaven / Form 8-K, 4 September hold and separate study timelines](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm)
13. [SEC / Biohaven filing history; September report filed 10 September and signed 9 September](https://data.sec.gov/submissions/CIK0001935979.json)

## October Removed an Antitrust Wait, Not the Clinical Question

Biohaven's 29 October results provided the next dated development. The applicable Hart-Scott-Rodino waiting period had expired on 28 October, allowing the parties to complete remaining closing conditions. The same update still described new enrolment as paused and additional nonclinical work as pending. Its filing continued to describe the licence as effective upon closing.

The additional nonclinical studies remained central to the next research decision: whether more patients could enter the programme. Biohaven continued to expect RISE3 topline results in the second half of 2026. Lee and Coric were still working towards a transaction whose leading candidate faced that unresolved safety assessment, even as the antitrust process advanced.

11. [Biohaven / 29 October 2026 update, HSR expiry and continuing partial hold](https://biohaven.gcs-web.com/news-releases/news-release-details/biohaven-reports-recent-business-developments-and-third-quarter)
12. [Biohaven / Q3 2026 Form 10-Q, licence note and metabolite partial hold](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000092/bhvn-20260930.htm)

## Cenobamate Was Expanding While the New Candidate Waited

Meanwhile, the existing medicine reached another regulatory milestone. Ono received Japanese manufacturing and marketing approval for cenobamate on 16 September. Its exclusive Japanese development and commercial rights came from the 2020 agreement with SK. SK said the approval triggered a contractual milestone, with the amount undisclosed, and that future Japanese sales would support royalties.

Ono supplies the Japanese commercial organisation, while SK participates through its licence. The Japanese label covers partial-onset seizures with or without secondary generalisation. Ono was also conducting Phase III studies in primary generalised tonic-clonic seizures and paediatric partial-onset seizures, pursuing further uses beyond that approval. In Japan, expanding the existing medicine meant continuing both local commercial preparation and clinical development.

The contrast captures SK's position in 2026. Cenobamate was supporting an expanding franchise through direct sales and regional partners. Opakalim was a prospective addition chosen to make the American organisation more useful, but it brought a new scientific question and substantial future payments. The commercial achievement gives Lee room to make that choice. It also makes the quality of the choice more consequential: an established earning business now has something substantial to reinvest and protect.

3. [SK Biopharmaceuticals / Japanese cenobamate approval and territorial monetization](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=803&currentPage=1)
4. [Ono Pharmaceutical / Japanese XCOPRI approval, label and exclusive local rights](https://www.ono-pharma.com/en/news/20260916.html)
1. [SK Biopharmaceuticals / Q2 2026 revenue, profit, product sales and prescription update](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=792&currentPage=1)

An effective, well-tolerated opakalim could give SK's epilepsy team another relevant option and reduce dependence on XCOPRI. That is the attraction behind the agreement, not a result already achieved. The partial hold and forthcoming trial data concern the candidate's merits, even while the existing franchise continues to grow.


### Primary Sources

1. [SK Biopharmaceuticals / Q2 2026 revenue, profit, product sales and prescription update](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=792&currentPage=1) (2026-08-05)

2. [SK Biopharmaceuticals / Q1 2026 earnings and US commercialization update](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=786&currentPage=1) (2026-05-07)

3. [SK Biopharmaceuticals / Japanese cenobamate approval and territorial monetization](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=803&currentPage=1) (2026-09-16)

4. [Ono Pharmaceutical / Japanese XCOPRI approval, label and exclusive local rights](https://www.ono-pharma.com/en/news/20260916.html) (2026-09-16)

5. [SK Biopharmaceuticals / opakalim agreement, payment schedule and US sales infrastructure](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=794&currentPage=1) (2026-08-26)

6. [SK Biopharmaceuticals / opakalim partial clinical hold and pre-closing status notice](https://www.skbp.com/kor/news/view.do?boardCode=BDCD0002&boardSeq=800&currentPage=1) (2026-09-10)

7. [Biohaven / Form 8-K, payment, development and termination terms](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/bhvn-20260826.htm) (2026-08-26)

8. [Biohaven / Form 8-K, 4 September hold and separate study timelines](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm) (2026-09-10)

9. [Biohaven and SK / joint release, commercial organisation and financial obligations](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/exhibit991-biohavenandskbi.htm) (2026-08-26)

10. [Biohaven and SK / partial assignment, obligations effective upon closing](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/exhibit102-partialmipaassi.htm) (2026-08-26)

11. [Biohaven / 29 October 2026 update, HSR expiry and continuing partial hold](https://biohaven.gcs-web.com/news-releases/news-release-details/biohaven-reports-recent-business-developments-and-third-quarter) (2026-10-29)

12. [Biohaven / Q3 2026 Form 10-Q, licence note and metabolite partial hold](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000092/bhvn-20260930.htm) (2026-10-29)

13. [SEC / Biohaven filing history; September report filed 10 September and signed 9 September](https://data.sec.gov/submissions/CIK0001935979.json) (2026-09-10)
